Morgan Stanley
BLTE

Morgan Stanley’s Belite Bio BLTE Stock Holding History

Morgan Stanley’s Portfolio BLTE Stock Details BLTE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.2M Buy
235,071
+33,662
+17% +$5.16M ﹤0.01% 2531
2026
Q1 		$32.1M Buy
201,409
+173,396
+619% +$29.2M ﹤0.01% 2526
2025
Q4 		$4.48M Buy
28,013
+22,783
+436% +$2.7M ﹤0.01% 4258
2025
Q3 		$387K Buy
5,230
+4,723
+932% +$310K ﹤0.01% 5617
2025
Q2 		$29.3K Buy
507
+191
+60% +$11.7K ﹤0.01% 6520
2025
Q1 		$20.9K Sell
316
-10,302
-97% -$621K ﹤0.01% 6559
2024
Q4 		$670K Buy
10,618
+9,956
+1,504% +$656K ﹤0.01% 5296
2024
Q3 		$31K Sell
662
-382
-37% -$18.5K ﹤0.01% 6354
2024
Q2 		$47.7K Sell
1,044
-5,046
-83% -$218K ﹤0.01% 6191
2024
Q1 		$234K Sell
6,090
-16,331
-73% -$731K ﹤0.01% 5682
2023
Q4 		$1.03M Buy
22,421
+21,983
+5,019% +$845K ﹤0.01% 4910
2023
Q3 		$13.9K Hold
438
– – ﹤0.01% 6601
2023
Q2 		$6.26K Sell
438
-600
-58% -$13.6K ﹤0.01% 6933
2023
Q1 		$31K Sell
1,038
-962
-48% -$29.2K ﹤0.01% 6460
2022
Q4 		$60.3K Sell
2,000
-16,308
-89% -$481K ﹤0.01% 6210
2022
Q3 		$615K Buy
+18,308
New +$633K ﹤0.01% 5162

Other funds holding BLTE

DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Holocene Advisors
Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley's BLTE Position: Q2 2026 in Review

Morgan Stanley increased its Belite Bio (BLTE) stake by 17% in Q2 2026, buying an estimated $5.16M and bringing the position to 235,071 shares worth $36.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2531.

Morgan Stanley first reported a position in BLTE in Q3 2022 and has held it in 16 quarters since. 80 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

  • Morgan Stanley held 235,071 shares of Belite Bio worth $36.2M as of Q2 2026.
  • Morgan Stanley bought 33,662 Belite Bio shares in Q2 2026, an estimated $5.16M.
  • Belite Bio made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2531 holding.
  • Morgan Stanley first reported a position in Belite Bio in Q3 2022 and has held it in 16 quarters since.
  • 80 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.